Press "Enter" to skip to content

USFDA issues 12 observations for 3 Biocon units in Malaysia

Biocon Sdn Bhd’s insulin glargine drug substance, drug product, and device assembly facilities in Malaysia underwent a pre-approval inspection by the USFDA between June 24 and July 5, 2019, Biocon said in a filing to BSE.

Original source: https://health.economictimes.indiatimes.com/news/pharma/usfda-issues-12-observations-for-3-biocon-units-in-malaysia/70126922?utm_source=RSS&utm_medium=ETRSS

Also Read:   Abbott wins U.S. approval for rapid Covid-19 test